Welcome to our dedicated page for Xenon Pharmaceut SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company developing azetukalner and other ion channel modulators for epilepsy, major depressive disorder (MDD), bipolar depression (BPD), and pain. As a foreign private issuer incorporated in Canada and listed on The Nasdaq Global Market, Xenon uses SEC reports to disclose financial results, executive changes, and other material events.
Among the key documents available here are Form 8-K filings, which Xenon uses to report quarterly financial results, business updates, and corporate developments such as the appointment of its Chief Financial Officer and related employment and equity arrangements. These filings often reference the company’s Phase 3 clinical programs in focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), MDD, and BPD, as well as its early-stage NaV1.7, Kv7, and NaV1.1 programs.
Investors can also review exhibits attached to 8-Ks, including press releases that summarize results of operations and financial condition, R&D spending, and cash runway expectations, along with risk-focused forward-looking statements. Additional filings detail governance and compensation matters, such as severance protections and equity inducement grants made under Xenon’s inducement equity incentive plans.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI-powered summaries that highlight key points, explain technical language, and help users quickly identify information about Xenon’s clinical pipeline, executive changes, and financial disclosures. Users can also locate information relevant to insider and equity-related activity through option and restricted share unit grant disclosures contained in the company’s current reports.
Xenon Pharmaceuticals Inc. Chief Medical Officer Christopher John Kenney reported routine equity compensation activity and a small open-market sale. On March 12, 2026, he exercised 3,750 Restricted Share Units at $0.00 per share, converting them into 3,750 Common Shares that had vested from a grant made on March 12, 2025.
The RSU award vests in four equal annual installments starting on March 12, 2026, and after this vesting he held 11,250 Restricted Share Units directly. On March 13, 2026, he sold 1,410 Common Shares at an average price of $55.225 per share under a Rule 10b5-1 durable sell-to-cover instruction adopted on December 3, 2025, solely to satisfy tax withholding obligations related to the RSU vesting. Following these transactions, he directly owned 7,069 Common Shares.
Xenon Pharmaceuticals Inc.’s Chief Legal Officer, Andrea DiFabio, reported routine equity compensation activity. On March 12, 2026, 3,750 restricted share units granted on March 12, 2025 vested and were converted into an equal number of common shares at no cost. On March 13, 2026, 1,342 common shares were sold at $55.225 per share pursuant to a pre-arranged Rule 10b5-1 “sell-to-cover” instruction used solely to satisfy tax withholding on the RSU vesting. After these transactions, DiFabio holds 7,301 common shares directly and 11,250 RSUs remain outstanding under the award, vesting in equal annual installments over four years beginning March 12, 2026.
Xenon Pharmaceuticals Inc. President & CEO Ian Mortimer reported a combination of equity compensation and a small share sale. On March 12, 2026, RSUs covering 12,500 Common Shares vested and were exercised at $0, increasing his direct shareholdings. On March 13, 2026, he executed an open-market sale of 7,308 Common Shares at $55.225 per share under a pre-arranged Rule 10b5-1 “sell-to-cover” instruction adopted on December 3, 2025, solely to satisfy tax withholding tied to the RSU vesting. Following these transactions, Mortimer holds 19,923 Common Shares directly and 14,300 Common Shares indirectly through his spouse, along with 37,500 Restricted Share Units that remain outstanding.
Morgan Stanley Wealth Management Canada Inc. filed a Form 144 notifying the sale of Common Shares tied to a Restricted share unit award vesting dated 03/12/2026 for 3,750 shares. The notice also lists a 03/10/2026 sale of 2,771 shares by Andrea DiFabio and a reported figure 166,559 appearing in the securities block.
XENE Rule 144 notice reporting proposed and recent transactions in Common Shares. The filing lists 3,750 Restricted Share Units vesting on 03/12/2026 and shows 2,607 Common Shares sold by Andrea DiFabio on 03/10/2026.
Ian Mortimer reported dispositions of Common Shares. The filing lists sales of 40,000 shares on 01/02/2026, 270,000 shares on 03/09/2026, and 11,269 shares on 03/10/2026. It also shows a 12,500 restricted share unit award vesting on 03/12/2026.
Xenon Pharmaceuticals Inc. outlined key details for its 2026 annual meeting of shareholders. The meeting is scheduled for June 2, 2026, with a record date for notice and voting of April 7, 2026, which is also the beneficial ownership determination date.
Holders of Xenon common shares are entitled to receive notice of and vote at the meeting. The company will not mail materials directly to non-objecting beneficial owners but will pay for distribution to objecting beneficial owners. Xenon is using notice-and-access for both registered and non-registered investors, and the related information was also submitted through a SEDAR+ filing furnished as Exhibit 99.1.
Xenon Pharmaceuticals Inc. completed a large equity financing, raising approximately $707.7 million in net proceeds from an underwritten public offering of common shares and pre-funded warrants. The company sold 12,236,843 common shares and pre-funded warrants to purchase 877,194 common shares, plus an additional 1,710,526 common shares after underwriters fully exercised their 30-day option.
The public offering price was $57.00 per common share and $56.9999 per pre-funded warrant, with underwriters purchasing at discounted prices. The pre-funded warrants have a $0.0001 exercise price, may be exercised for cash or on a cashless basis, and include a beneficial ownership cap initially set at 4.99%, adjustable by the holder up to 19.99% with advance notice. The warrants also provide protections and alternate consideration in certain major corporate transactions.
Xenon Pharmaceuticals Inc. reported that Chief Medical Officer Christopher John Kenney had performance share units (PSUs) granted on March 11, 2024 vest after the board determined milestone achievement. These PSUs, totaling 7,500 units, immediately converted into 7,500 common shares.
Following this vesting, Kenney sold 2,771 common shares on March 10, 2026 at an average price of $60.108 per share under a Rule 10b5-1 durable sell-to-cover instruction adopted on December 3, 2025 solely to satisfy tax withholding obligations related to the PSU vesting. After these transactions, he directly holds 4,729 common shares.
Xenon Pharmaceuticals Inc. Chief Legal Officer Andrea DiFabio reported equity compensation vesting and a related share sale. On March 9, 2026, 7,500 Performance Share Units vested based on the Board’s milestone assessment and were converted into 7,500 Common Shares at $0.00 per share.
On March 10, 2026, DiFabio sold 2,607 Common Shares in an open‑market transaction at an average price of $60.108 per share under a pre‑arranged Rule 10b5‑1 sell‑to‑cover instruction to satisfy tax withholding on the PSU vesting, leaving 4,893 Common Shares held directly.